Who is eligible for clinical trial NCT07037758?

Participants must meet the protocol's inclusion criteria for Extensive Stage Small Cell Lung Cancer. The stated age range is 18 Years to 90 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07037758 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-27

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (NCT07037758)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Amgen

🩺 Plain-English Summary (8th-Grade Level)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).

Location: Banner MD Anderson Cancer Center — Gilbert, Arizona

Age range: 18 Years to 90 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Participant has provided informed consent before initiation of any study-specific activities/procedures.
Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
Participants with histologically or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therapy for ES-SCLC.
Participants must have at least 1 measurable lesion as defined by RECIST 1.1 within 21-day screening period, not previously irradiated.
Participants must have adequate organ function (hematological, coagulation, cardiac, pulmonary, kidney, and liver).
Participants must submit a fresh tumor biopsy at screening unless a new biopsy cannot be performed safely or is infeasible. Participants who cannot provide fresh tissue may provide archival tissue that was collected after last anticancer therapy.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Symptomatic central nervous system (CNS) metastases.
Participants with brain metastases may be eligible if criteria defined in the protocol are met.
Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy (including tarlatamab).
Prior interleukin (IL)-2, IL-7 or IL-15 targeted therapy.
Baseline (at rest) requirement of supplemental oxygen.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (19 Sites)

Banner MD Anderson Cancer Center — Gilbert, Arizona
University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
Moffitt Cancer Center — Tampa, Florida
Emory University — Atlanta, Georgia
Norton Cancer Institute - Downtown — Louisville, Kentucky
Dana-Farber Cancer Institute — Boston, Massachusetts
Siteman Cancer Center — St Louis, Missouri
Memorial Sloan Kettering Cancer Center — New York, New York
Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
Allegheny General Hospital — Pittsburgh, Pennsylvania
Avera Cancer Institute — Sioux Falls, South Dakota
Baptist Cancer Center — Memphis, Tennessee
Swedish Cancer Institute Medical Oncology — Seattle, Washington
Chungbuk National University Hospital — Cheongju Chungbuk,
Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do,
Severance Hospital Yonsei University Health System — Seoul,
Adana Sehir Egitim ve Arastirma Hastanesi — Adana,
Hacettepe Universitesi Tip Fakultesi Hastanesi — Ankara,
Ankara Bilkent Sehir Hastanesi — Ankara,

📞 Contact the Study Coordinator

Phone: (866) 572-6436

Email: medinfo@amgen.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive Stage Small Cell Lung Cancer

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC — Birmingham, Alabama
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab — Orlando, Florida
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Los Angeles, California
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer — Chicago, Illinois
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — Los Angeles, California

Explore by condition: All Extensive Stage Small Cell Lung Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗